期刊论文详细信息
EMBO Molecular Medicine
Atrial‐like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial‐selective pharmacology
Harsha D Devalla4  Verena Schwach4  John W Ford1  James T Milnes1  Said El-Haou1  Claire Jackson1  Konstantinos Gkatzis4  David A Elliott3  Susana M Chuva de Sousa Lopes4  Christine L Mummery4  Arie O Verkerk2 
[1] Xention Ltd, Cambridge, UK;Heart Failure Research Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Vic., Australia;Department of Anatomy & Embryology, Leiden University Medical Center, Leiden, The Netherlands
关键词: arrhythmias;    atrial cardiomyocytes;    atrial fibrillation;    COUP‐TF;    ion channels;   
DOI  :  10.15252/emmm.201404757
来源: Wiley
PDF
【 摘 要 】

Abstract

Drugs targeting atrial-specific ion channels, Kv1.5 or Kir3.1/3.4, are being developed as new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried out in non-cardiac cell lines or animal models may not accurately represent the physiology of a human cardiomyocyte (CM). In the current study, we tested whether human embryonic stem cell (hESC)-derived atrial CMs could predict atrial selectivity of pharmacological compounds. By modulating retinoic acid signaling during hESC differentiation, we generated atrial-like (hESC-atrial) and ventricular-like (hESC-ventricular) CMs. We found the expression of atrial-specific ion channel genes, KCNA5 (encoding Kv1.5) and KCNJ3 (encoding Kir 3.1), in hESC-atrial CMs and further demonstrated that these ion channel genes are regulated by COUP-TF transcription factors. Moreover, in response to multiple ion channel blocker, vernakalant, and Kv1.5 blocker, XEN-D0101, hESC-atrial but not hESC-ventricular CMs showed action potential (AP) prolongation due to a reduction in early repolarization. In hESC-atrial CMs, XEN-R0703, a novel Kir3.1/3.4 blocker restored the AP shortening caused by CCh. Neither CCh nor XEN-R0703 had an effect on hESC-ventricular CMs. In summary, we demonstrate that hESC-atrial CMs are a robust model for pre-clinical testing to assess atrial selectivity of novel antiarrhythmic drugs.

Synopsis

image

Newly generated human embryonic stem cell-derived atrial-like cardiomyocytes resemble human atrial cardiomyocytes and prove to be a valuable model for pre-clinical drug screenings to identify effective atrial-selective compounds against atrial fibrillation.

  • Exogenous addition of retinoic acid drives differentiating human embryonic stem cells towards atrial-like cardiomyocytes.
  • COUP-TFI and COUP-TFII are induced during atrial differentiation.
  • COUP-TF transcription factors regulate atrial-specific ion channel genes.
  • hESC-atrial CMs respond to drugs targeting atrial-selective ion channels.

【 授权许可】

CC BY   
© 2015 The Authors. Published under the terms of the CC BY 4.0 license

Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

【 预 览 】
附件列表
Files Size Format View
RO202107150009564ZK.pdf 4034KB PDF download
  文献评价指标  
  下载次数:2次 浏览次数:5次